Abstract
Background
Despite its high prevalence, practice-based data on management and outcomes after cancer-associated pulmonary embolism (PE) are scarce, and no studies have investigated quality of life.
Objectives
We aimed to evaluate clinical outcomes, anticoagulation practice patterns, and quality of life after cancer-associated PE.
Methods
The Hydra randomized clinical trial assessed the safety of the YEARS algorithm versus computed tomography pulmonary angiography only to exclude acute PE in patients with cancer. Patients with PE at baseline or during 90-day follow-up were included in this study. Outcomes were recurrent venous thromboembolism, major bleeding, all-cause mortality, anticoagulation practice patterns, and quality of life as assessed by the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire. PEmb-QoL scores were compared with those for the general PE population reported in the FOCUS study. Lower scores indicate better QoL.
Results
A total of 125 patients were included, of which 103 (82%) had PE at baseline, and 22 (18%) developed PE during follow-up. The 90-day cumulative incidence of recurrent venous thromboembolism and major bleeding was 2.5% (95% CI 0.67%-6.6%) and 2.5% (95% CI 0.68%-6.7%), respectively. All-cause mortality at 90 days was 32% (95% CI 23%-40%). Two-thirds of patients continued anticoagulation until less than 24 hours before death, and the median time between stopping anticoagulation and death was 10 days (IQR, 4-14). The median 90-day PEmb-QoL score was 33% (IQR, 13-51) versus 20% (IQR, 10-40) reported in the FOCUS study.
Conclusion
Patients with cancer-associated PE suffer from high mortality, high morbidity, and impaired quality of life. Anticoagulation therapy is frequently continued until the last days of life.
Keywords: anticoagulants, hemorrhage, neoplasm, pulmonary embolism, venous thromboembolism
Essentials
-
•
Data on management and quality of life after cancer-associated pulmonary embolism are scarce.
-
•
Data from the Hydra study, which assessed the YEARS algorithm in patients with cancer, were used.
-
•
Recurrent thrombosis, bleeding, and mortality were frequent.
-
•
Anticoagulation was frequently continued until death and quality of life after pulmonary embolism was impaired.
1. Introduction
Patients with cancer face an elevated risk of venous thromboembolism (VTE), which has been increasing over the past decades [1]. Although anticoagulation is standard care for cancer-associated VTE, it is associated with a high risk of bleeding, and recurrent VTE still occurs often in this group of patients [2], [3], [4]. This is especially relevant for patients with end-stage cancer, who have been systematically excluded from most clinical trials on anticoagulation treatment for pulmonary embolism (PE) and also other conditions requiring anticoagulation, such as atrial fibrillation and deep vein thrombosis [5], [6], [7].
Consequently, physicians lack clear, evidence-based guidance on the risks and benefits of anticoagulation during end-of-life care in patients with cancer. To address this uncertainty, the Europe-wide Serenity Project was launched. Its goal is to develop and validate a clinical decision-support tool to guide discussions about continuing or discontinuing anticoagulation as patients with cancer approach the end of life [7]. As part of this effort, several descriptive studies have analyzed European nationwide databases to better understand current antithrombotic treatment patterns during end-of-life care [8], [9], [10].
Beyond clinical outcomes, PE is also known to impair quality of life [11], [12], [13], [14], and this impact may be even more pronounced in patients with cancer due to their higher vulnerability and poorer overall prognosis. Studies on quality of life after PE have included only a minority of patients with cancer, limiting the generalizability of findings to this high-risk group [11], [12], [13]. Therefore, a dedicated study assessing quality of life after cancer-associated PE is needed.
In the present paper, we report on clinical outcomes, anticoagulation practice patterns, and quality of life after cancer-associated PE. Furthermore, the current study aims to support the Serenity Project by providing additional data on anticoagulation-related outcomes and treatment complications during end of life in patients with cancer-associated PE.
2. Methods
2.1. Hydra study
The design and methods of the Hydra study have previously been published (International Clinical Trials Platform registry number: NL-OMON52383) [15]. Briefly, the Hydra study was a randomized, investigator-initiated, noninferiority trial with blinded central outcome adjudication, involving 21 hospitals in 6 countries (the Netherlands, Italy, Switzerland, France, Spain, and Belgium). From August 22, 2019, to May 23, 2025, 698 patients were recruited from emergency departments, outpatient clinics, and during hospitalization. The trial showed that in patients with cancer, a diagnostic strategy using the YEARS algorithm was as safe as computed tomography pulmonary angiography (CTPA) only for excluding acute PE, while obviating the need to perform a CTPA in 22% of patients [16]. All participants provided written informed consent before randomization, and the study was approved by the institutional review board of each participating center. This paper describes the predefined secondary outcomes of the Hydra study.
Patients 18 years or older with active cancer and a clinical suspicion of acute PE were eligible for inclusion. Active cancer was defined as a cancer diagnosis confirmed by histology or strongly suspected by a clinician within 6 months before study inclusion; ongoing cancer treatment at the time of inclusion; cancer treatment received within 6 months before randomization; or the presence of metastatic disease. Patients were excluded if they had therapeutic anticoagulation for indications other than acute PE, had prior participation in the study, had PE diagnostics initiated because of a suggestion of PE on a previously performed radiological scan, were hemodynamically unstable, had contraindications to CTPA, were participating in a concurrent study on thromboprophylaxis, or if they had an expected life expectancy of less than 3 months.
For this analysis, we included all patients with acute symptomatic or incidental PE diagnosed at baseline or during follow-up, or PE-related death during follow-up. PE was defined as an intraluminal filling defect in a subsegmental or more proximal pulmonary artery on CTPA or a mismatch between ventilation and perfusion with a perfusion defect at a segmental or more proximal level on a ventilation-perfusion scan. PE-related death was defined as any death adjudicated as either certain PE-related or possible PE-related (ie, unexplained) death adjudicated according to the International Society on Thrombosis and Haemostasis (ISTH) definition for PE-related death [15], [17].
2.2. Outcomes
Patients were instructed to contact study personnel or the emergency department in case of signs or symptoms suggestive of VTE or major bleeding (MB) during follow-up. Every patient also received a follow-up telephone call at 90 days (±7 days) to ask about signs and symptoms suggestive of recurrent VTE or MB and to evaluate anticoagulation practice patterns. If the patient did not answer, the general practitioner and/or primary cancer physician were contacted.
All suspected recurrent VTE and MB during follow-up were adjudicated by HtC and KH. Disagreements were resolved by discussion, and if necessary, a third thrombosis expert was consulted. VTE was incidental if it was detected by means of imaging tests performed for reasons other than clinical suspicion of VTE.
Recurrent VTE was defined as [18]:
-
•
a new intraluminal filling defect or an extension of an existing defect; or
-
•
an area of noncompressibility in a venous segment where compression had been normal; or
-
•
a significant increase (>4 mm) in vein diameter of a previous noncompressible segment upon compression ultrasound.
MB was defined according to the ISTH definition [19]:
fatal; and/or associated with any of the following:
-
•
a fall in hemoglobin level of >2 g/dL (ie, >1.24 mmol/L); or
-
•
documented transfusion of >2 units of packed red blood cells or whole blood; or
-
•
involvement of a critical area or organ, such as intracranial, spinal, ocular, pericardial, articular, intramuscular with compartment syndrome, or retroperitoneal.
Additionally, 90 days (±7 days) after inclusion in the Hydra trial, all patients with PE at baseline or during follow-up were asked to complete the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire. The PEmb-QoL questionnaire was initially developed and validated in Dutch and English to specifically measure PE-related quality of life [20], [21], and was subsequently translated and validated in French [22] and German [23], and has also been translated into Spanish and Italian. The questionnaire assesses health-related quality of life in six dimensions: frequency of complaints, limitation in activities of daily living (ADL), work-related problems, social limitations, intensity of complaints, and emotional complaints. Percentage scores (0-100) were calculated for each dimension as well as an overall score, with a higher score indicating a worse quality of life. PEmb-QoL is one of the central instruments from the International Consortium for Health Outcomes Measurement standard set of outcome measures for patients with VTE [24]. As an exploratory analysis, the scores were graphically compared with the 3-month PEmb-QoL scores after PE in the FOCUS study from the population of all-comers [12].
2.3. Focus study
The FOCUS study (German Clinical Trials Registry number DRKS00005939) prospectively included 1098 consecutive unselected patients with a confirmed diagnosis of acute symptomatic PE between September 2014 and October 2018 at 17 large-volume centers across Germany. Patients were followed up over a 2-year period and were treated according to the standard of care at the participating centers without any specific mandates from the study protocol [12], [25]. The current analysis included patients who had completed at least one item in all numeric dimensions of the 40-item PEmb-QoL questionnaire at the 3-month visit.
2.4. Statistical analysis
Patient characteristics and anticoagulation practice patterns were described using means with SD or medians with IQR as appropriate for continuous variables and counts with percentages for categorical variables. The Kaplan–Meier estimator was used to estimate 30-day and 90-day all-cause mortality. The incidence of recurrent VTE and MB was estimated using the cumulative incidence function in which death was considered a competing risk. The date of PE diagnosis was used as the index date. The PEmb-QoL scores were calculated for each dimension by summing up the item values divided by the number of items. If a question was missing, the concurrent dimension was not calculated for that patient. The overall score was calculated by averaging the score for each dimension. Anticoagulation practice patterns were only described for patients with confirmed PE on imaging.
No imputation for missing data was performed. We used R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria) for all statistical analyses. Cumulative incidences were estimated using the tidycmprsk package.
3. Results
3.1. Study population
A total of 125 patients with cancer-associated PE were included, of whom 103 (82%) had acute PE diagnosed at baseline and 22 (18%) during follow-up, of which 9 were symptomatic PE, 3 were incidental (ie, unsuspected) PE, and 10 were PE-related deaths. Baseline characteristics are summarized in Table. The median age at baseline was 66 years (IQR, 59-73), and 72 (58%) patients were female. A history of VTE was reported in 10 (8.0%) patients, and 19 (16%) had undergone recent surgery (<1 month). Regarding the largest vessel involved, PE was central in 35 (30%) patients, segmental in 54 (47%), and subsegmental in 26 (23%). Of the patients with PE at baseline, 22 (21%) were discharged within 24 hours. No patients were lost to follow-up; data on anticoagulation management during follow-up were missing for 2 patients.
Table.
Baseline characteristics
| Number of patients | 125 |
|---|---|
| Age (years) | 66 (59,73) |
| Female sex | 72 (58) |
| Body mass index | 26 (23,30) |
| Smoking history | |
| No | 60 (48) |
| Former | 50 (40) |
| Current | 15 (12) |
| Antiplatelet therapya | 19 (15) |
| History of venous thromboembolism | 10 (8.0) |
| Recent surgery | 19 (16) |
| Symptomatic PE | 122 (98) |
| Incidental PE | 3.0 (25) |
| Largest vessel involved | |
| Central | 35 (30) |
| Segmental | 54 (47) |
| Subsegmental | 26 (23) |
| Primary cancer site | |
| Breast | 17 (14) |
| Lung | 34 (27) |
| Upper gastrointestinal tract | 8.0 (6.4) |
| Lower gastrointestinal tract | 13 (10) |
| Genitourinary tract | 31 (25) |
| Brain | 4.0 (3.2) |
| Hematological | 11 (8.8) |
| Melanoma skin cancer | 3.0 (2.4) |
| Other | 9.0 (7.2) |
| Anticancer therapy in previous 6 months | |
| Chemotherapy | 71 (57) |
| Surgery | 25 (20) |
| Radiation therapy | 18 (14) |
| Immunotherapy | 35 (28) |
| Hormone therapy | 7.0 (5.6) |
| No anticancer therapy | 15 (12) |
| Cancer stage | |
| Localized | 25 (20) |
| Regional | 25 (20) |
| Distant metastases | 67 (54) |
| Comorbidities | |
| Hypertension | 49 (39) |
| Diabetes mellitus | 15 (12) |
| COPD | 18 (14) |
| Ischemic heart disease | 7.0 (5.6) |
| Stroke | 8.0 (6.4) |
| Heart failure | 2.0 (1.6) |
| Rheumatic or other autoimmune disease | 5.0 (4.0) |
| Presenting symptoms | |
| Dyspnea | 99 (85) |
| Chest pain | 57 (49) |
| Syncope | 10 (8.8) |
| Hemoptysis | 9.0 (7.8) |
| Palpitations | 13 (12) |
Data are n (%), or median (IQR).
COPD, chronic obstructive pulmonary disease; PE, pulmonary embolism.
No data on changes in antiplatelet therapy after baseline are available.
3.2. Anticoagulation practice patterns
Of the 115 patients with symptomatic or incidental PE diagnosed on imaging, 64 (56%) patients were treated with a direct oral anticoagulant (DOAC). Forty-three (37%) patients were initially treated with low-molecular-weight heparin (LMWH), of which 13 (33%) remained on LMWH at the end of follow-up, 25 (64%) were transitioned to a DOAC, 1 (2.6%) was transitioned to a vitamin K antagonist, 3 (7.0%) patients discontinued anticoagulation, and for 1 (2.6%) patient data were missing. The median time to transition from LMWH to DOAC was 6 (IQR, 3-19) days. Four (3.5%) patients were treated with unfractionated heparin, and all were transitioned to a DOAC by the end of follow-up. Two (1.7%) patients were treated with a vitamin K antagonist. Two (1.7%) patients had a subsegmental PE and a high risk of bleeding and therefore did not receive anticoagulation therapy. Neither experienced recurrent VTE or MB or died during the follow-up period. Anticoagulation management during initial diagnosis of PE and at the end of follow-up is illustrated in Figure 1.
Figure 1.

Alluvial diagram visualizing anticoagulation changes from PE diagnosis to end of follow-up. DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin, VKA, vitamin K antagonist.
3.3. Clinical outcomes and anticoagulation management during end of life
After cancer-associated PE, 39 patients died during follow-up, of whom 10 died because of PE. The 30- and 90-day all-cause mortality were 22% (95% CI, 14%-29%) and 32% (95% CI, 23%-40%), respectively (Figure 2). Anticoagulation was continued until at least 24 hours prior to death in 70% (n = 21, 95% CI, 50%-85%) of patients who initially started anticoagulation. Reasons for stopping anticoagulation were end-of-life care (n = 6), bleeding complications (n = 2), and severe thrombocytopenia (n = 1). If anticoagulation was stopped more than 24 hours prior to death, the median number of days between stopping anticoagulation and death was 10 (IQR, 4-14). For 1 additional patient, anticoagulation was stopped because of end-of-life care 81 days after PE diagnosis. This patient was still alive at the end of the follow-up period.
Figure 2.

Cumulative survival probability after cancer-associated PE with 95% confidence interval.
Three patients had recurrent VTE, all of which were nonfatal PE. Two were on DOAC during the VTE recurrence and were transferred to LMWH; one was on a DOAC, which was discontinued by the patient without consulting a physician and restarted on VTE recurrence. Three patients had a (nonfatal) MB during follow-up, all of which were during treatment with LMWH. One had an adrenal hemorrhage, 1 had an intramuscular hemorrhage of the right upper leg, and 1 had an intraabdominal bleed. Two patients stopped anticoagulation therapy indefinitely, and the third patient was transferred to a DOAC. The cumulative incidence of recurrent VTE and MB at 90 days was 2.5% (95% CI, 0.67%-6.6%) and 2.5% (95% CI, 0.68%-6.7%), respectively.
3.4. Quality of life
A total of 85 patients with acute PE at baseline or during follow-up did not die and were therefore eligible to complete the PEmb-QoL questionnaire. Of these, 67 (79%) patients completed the questionnaire. Reasons for not completing the questionnaire were: not sent by study personnel (n = 4), patient refused (n = 5), no response (n = 6), end-of-life care (n = 1), and unknown (n = 2). The results of the PEmb-QoL questionnaire for each dimension can be found in Figure 3. The median overall PEmb-QoL score was 33% (IQR, 13-51) versus a median score of 20% (IQR, 10-40) in the FOCUS study. For the Hydra study, the median scores for each individual dimension were 12% for frequency of complaints, 50% for limitation in ADL, 75% for work-related problems, 25% for social limitations, 20% for intensity of complaints, and 18% for emotional complaints. For the FOCUS study, the median scores were 20% for frequency of complaints, 25% for limitation in ADL, 0% for work-related problems, 0% for social limitations, 24% for intensity of complaints, and 20% for emotional complaints.
Figure 3.

Distribution of dimension-specific and overall QoL as assessed by the PEmb-QoL score at 90 days of our study in blue and the FOCUS study by Valerio et al. [12] in red. Higher PEmb-QoL scores reflect decreased quality of life. AD, activity of daily life (ADL) limitations; EC, emotional complaints; FO, frequency of complaints; IO, Intensity of complaints; QoL, quality of life; SL, social limitations; WR, work-related problems.
4. Discussion
In this study, we found high mortality and morbidity in the first 90 days after cancer-associated PE. Approximately one-third of patients died, and 5% suffered either recurrent VTE or MB. For the patients who died during follow-up, the majority continued with therapeutically dosed anticoagulation up to the last days of life. Lastly, patients exhibited a noticeable impairment of their quality of life after PE.
The 90-day cumulative incidences of recurrent VTE and MB were 2.5% (n = 3, 95% CI, 0.67%-6.6%) and 2.5% (n = 3, 95% CI, 0.68%-6.7%), respectively. The incidence of VTE appears similar to the incidence reported in the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry (3.0%) and slightly lower than the incidence reported in a post hoc analysis of the CARAVAGGIO trial (5.3%), which could possibly be explained by increased testing for VTE in the CARAVAGGIO trial environment [26]. The incidence of MB appears to be similar to the incidence reported in the RIETE registry (3.4%) and the post hoc analysis of the CARAVAGGIO trial (2.9%) [26]. Importantly, the wide confidence intervals preclude strong conclusions.
After cancer-associated PE, nearly all patients were treated with anticoagulation. The majority were treated with a DOAC, but some of the patients received LMWH. Possible reasons for LMWH therapy could be the presence of gastrointestinal or genitourinary malignancy, a perceived “high-risk” PE, or an inclusion date before the publication of the 2020 Dutch guideline that allowed for the use of DOAC as an alternative to LMWH [5], [6], [27]. Our sample size precludes formal analyses to dissect these options, and these hypotheses cannot be formally tested.
Approximately 70% of patients continued anticoagulation until less than 24 hours before death, which on first glance is similar to what is reported in the literature for cancer-associated thrombosis [28], and also for patients with cancer and an indication for anticoagulation that is not PE [8], [9], [29]. However, the median time between stopping anticoagulation and death in our study was 10 days. Since the nationwide studies from the Serenity Project use data on pharmacy dispensations to determine anticoagulation use, most of the patients who stopped anticoagulation in our study would have remained undetected in these studies [8], [9]. The real discontinuation rate in our study is therefore likely lower than in those studies, possibly because physicians are more hesitant to stop anticoagulation after a recent PE. Notably, the reasons given for discontinuation before death were similar to those reported in a post hoc analysis of the clinical trial Hokusai-VTE cancer [30]. In that study, a worsening performance status showed the strongest association with early discontinuation, consistent with “end-of-life care” being the most mentioned reason in our study.
The median overall PEmb-QoL score in our study was 33% (IQR, 13-51) versus a median score of 20% (IQR, 10-40) in the general PE population at the same follow-up time in the FOCUS study, suggesting at least a numerically worse quality of life in our study [12]. The difference in the overall score seems to be mainly driven by limitations in ADL, work, and social life. However, because of the nature of the study, we are not able to determine whether any difference is because PE has more negative effects on quality of life in patients with cancer or because of preexisting impairment caused by the cancer itself. In addition, the inclusion criteria differed considerably across the two studies. For this reason, we did not perform a formal statistical analysis to compare the PEmb-QoL scores, and our results should be interpreted as purely descriptive. Even so, the apparent difference in median overall score does not seem to exceed the minimal clinically important difference of 15% [31]. In spite of these limitations, we were still able to assess quality of life after cancer-associated PE, which is at least as impaired as in the general population with PE. It is notable that we found no clear differences in the frequency, intensity, or emotional nature of complaints. However, it remains unclear whether this reflects a true absence of differences or is due to other factors, such as a ceiling effect or patients attributing their complaints to cancer rather than pulmonary embolism.
A particular strength of our study is its prospective design and rigorous follow-up. All patients consented to the collection of their data from all health care providers, which enabled us to evaluate anticoagulation therapy during end-of-life care in the hospital, the home setting, and at the hospice. This allowed us to paint a complete picture of anticoagulation use and clinical outcomes after cancer-associated PE. Additionally, because of this rigorous follow-up, the response rate to the PEmb-QoL questionnaire was high, which allowed us to reliably assess quality of life after cancer-associated PE. Moreover, we included patients from 21 hospitals in different European countries, enhancing the generalizability of our findings.
Some limitations should be acknowledged. First, our population might be less representative because patients with a life expectancy of less than 3 months were excluded, which may partially have influenced the event rates. However, the 30-day mortality in our cohort of 19% (95% CI, 12%-25%) is very similar to the 14% (95% CI, 13%-16%) reported during the same time period in a Danish nationwide study, suggesting our study population is representative of the broader population [32]. Second, we have not collected data on antiplatelet treatment patterns during follow-up, which could have influenced the risk of bleeding in our population. Third, we only collected PEmb-QoL scores at 90 days following inclusion and are therefore unable to assess the further development of quality of life over time. Fourth, comparisons of QoL scores between our cohort and the FOCUS cohort are limited by substantial differences in population characteristics. Fifth, we did not collect any data on race and ethnicity, which limits the ability to assess generalizability, identify health disparities, and address potential biological or social factors influencing the results.
In conclusion, patients with cancer-associated PE suffer from a high mortality, a high incidence of recurrent VTE and MB, and an impaired quality of life within 90 days after diagnosis. Anticoagulation therapy is frequently continued until the last day of life.
Acknowledgments
Belgium: J. Raskin, J. Kwakkel, T. Lapperre, A. Hufkens, W. Spysschaert, I. Verhaegen, D. Balemans, C. Stessels (Antwerp), Canada: G. Le Gal, K. Vrotniakaite(Ottawa); France: E.R., R. Verdet, P. Stephan, P. Bourgeois, Z. Onivogui, P. Dias (Brest); I. Mahé, H. Salami, M. Chemouny, H. Helfer, N. Izirouel, S. Hadim, L. Plaisance (Colombes); O. Sanchez (Paris); L. Bertoletti (Saint-Etienne); Italy: C. Cavallaro, A. De’Errico, I. Peters (Rome); G. Costantino, F. Gianni, G. Ramponi (Milan); The Netherlands: M. ten Wolde, B. Appelman (Almere); S. Middeldorp, V.L.B.I. Jansen, V.R. Lanting, A. Strijdhorst (Amsterdam); M.L. Maas, M.M.C. Hovens (Arnhem); F. Kleijwegt, L.M. Faber, C. Bresser (Beverwijk); Z. Jaderi, A.W. Flikweert, B. van Steen, C. Peeters, M. Maas, M. Daalmans, M. Grootenboers (Breda); R.E. Brouwer, D.A. van Rijssel, E.M. van der Weert, C. Haazer, A. de Graaf, B. van Prooijen, E.B. van Druten, E.G. Gortmaker (Delft); K. van Elst, C.A. van Assen, E. Geraedts, M. Nagtegaal, A. ten Heuvel, R. Sluga (Gouda); M. de Vreede, Y. Ende, I. van der Plas, S. Jagernath (The Hague); C.M.M. de Jong, D. Luijten, S.F.B. van der Horst, J.F. Krommenhoek, R.M.A. Mali, S.N.M. ter Haar, L.J. op de Hoek, F.H.J. Kaptein, P.L. den Exter, T.E. van Mens, M. Stals, W.J.E. Stenger (Leiden); P.W. Kamphuizen, S. Moll, M. de Bruijn (Hilversum); E. Klappe, O. Sir (Nijmegen); A. Wei, A. Sanders, B. Raap, H. Peters (Uden); M. Deelen, JJC Drijkoningen, A. Aikema, H. Zanders, M. Hoogervorst (Utrecht); B. Jones, E.M.G. van Berkesteijn (Rotterdam); M.Out (Twente); Spain: W. Briceño; R. Morillo; C. Rodríguez-Calle (Madrid); Switzerland: C. Baumgartner, D. Pulver, S. Maurer (Bern); M. Righini, N. Koffi Malan Antoine (Geneva); M.J. Brochu Vez, H. Gerhard Donnet, O. Hugli, (Lausanne).
Funding
This trial was endorsed by INVENT-VTE, an independent not-for profit network of academic research groups that conduct VTE-related clinical research, and is funded through the INVENT 2021 Kickstarter Awards Grant and in-kind contributions from the participating hospitals. The study is part of the research project SERENITY – “Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life” (https://serenity-research.eu/). This project has received funding from the European Union's Horizon Europe research and innovation action under grant agreement No 101057292.Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or The European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Author Contributions
Concept and design: F.A.K., M.V.H. Acquisition of data: All authors. Analysis and interpretation of data: B.A., F.A.K., M.V.H. Drafting of the manuscript: B.A., M.V.H. Critical review of the manuscript for important intellectual content: All authors. Statistical analysis: B.A. Obtained funding: F.A.K., M.V.H. Administrative, technical, or material support: B.A., E.S.L.M. Supervision: F.A.K., M.V.H.
Relationship Disclosure
MVH has obtained research grant funding from the Dutch Health Care Fund, the Dutch Heart Foundation, Pfizer-BMS, Bayer Health Care, Leo Pharma, AngioDynamics, and Daiichi-Sankyo, all outside this work. F.A.K. has received research funding from Bayer, BMS, BSCI, AstraZeneca, MSD, Leo Pharma, Actelion, Varm-X, AngioDynamics, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Foundation, The Dutch Heart Foundation and the Horizon Europe Program, all outside this work and paid to his institution. JL reports consultancy fees from AstraZeneca and Viatris, speaker fees for BMS-Pfizer and research funding from Synapse. MC is principal investigator for studies at his center sponsored by Anthos, Bayer, CSL Behring and received payment for lectures by CSL Behring and Pfizer. All outside the current work and all funds were paid to his institution. All other authors have nothing to disclose.
Statement on The Use of Generative AI
During the preparation of this report, LeChat by Mistral was used in order to check spelling and grammar. After using this tool/service, we reviewed and edited the content as needed and take full responsibility for its content.
Footnotes
Handling Editor: Professor Michael Makris
References
- 1.Mulder F.I., Horváth-Puhó E., van Es N., van Laarhoven H.W.M., Pedersen L., Moik F., et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959–1969. doi: 10.1182/blood.2020007338. [DOI] [PubMed] [Google Scholar]
- 2.Kaptein F.H.J., Guman N.A.M., Lohle S.B., Klok F.A., Mairuhu A.T.A., Kamphuisen P.W., et al. Treatment patterns of cancer-associated thrombosis in the Netherlands: the four cities study. TH Open. 2024;8:e61–e71. doi: 10.1055/a-2214-8101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488. doi: 10.1182/blood-2002-01-0108. [DOI] [PubMed] [Google Scholar]
- 4.Kraaijpoel N., Bleker S.M., Meyer G., Mahé I., Muñoz A., Bertoletti L., et al. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an International Prospective Cohort Study. J Clin Oncol. 2019;37:1713–1720. doi: 10.1200/JCO.18.01977. [DOI] [PubMed] [Google Scholar]
- 5.Agnelli G., Becattini C., Meyer G., Muñoz A., Huisman M.V., Connors J.M., et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599–1607. doi: 10.1056/NEJMoa1915103. [DOI] [PubMed] [Google Scholar]
- 6.Raskob G.E., van Es N., Verhamme P., Carrier M., Di Nisio M., Garcia D., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–662. doi: 10.1056/NEJMoa1711948. [DOI] [PubMed] [Google Scholar]
- 7.Goedegebuur J., Abbel D., Accassat S., Achterberg W.P., Akbari A., Arfuch V.M., et al. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: a research protocol for the development and implementation of the SERENITY shared decision support tool. Thromb Res. 2023;228:54–60. doi: 10.1016/j.thromres.2023.05.008. [DOI] [PubMed] [Google Scholar]
- 8.Aldridge S.J., Akbari A., Edwards A., Lifford K.J., Abbel D., Cannegieter S., et al. Anti-thrombotic therapy in patients with cancer at the end of life: a cohort study using population-linked routinely collected data. Br J Haematol. 2025;207:2080–2090. doi: 10.1111/bjh.70032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Søgaard M., Ørskov M., Jensen M., Goedegebuur J., Kempers E.K., Visser C., et al. Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study. J Thromb Haemost. 2025;23:190–200. doi: 10.1016/j.jtha.2024.09.023. [DOI] [PubMed] [Google Scholar]
- 10.Kempers E.K., Visser C., Geijteman E.C.T., Goedegebuur J., Portielje J.E.A., Søgaard M., et al. Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease. Thromb Haemost. 2026;126:714–728. doi: 10.1055/a-2524-5334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.van Es J., den Exter P.L., Kaptein A.A., Andela C.D., Erkens P.M., Klok F.A., et al. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res. 2013;132:500–505. doi: 10.1016/j.thromres.2013.06.016. [DOI] [PubMed] [Google Scholar]
- 12.Valerio L., Barco S., Jankowski M., Rosenkranz S., Lankeit M., Held M., et al. Quality of life 3 and 12 months following acute pulmonary embolism: analysis from a prospective multicenter cohort study. Chest. 2021;159:2428–2438. doi: 10.1016/j.chest.2021.01.071. [DOI] [PubMed] [Google Scholar]
- 13.Keller K., Tesche C., Gerhold-Ay A., Nickels S., Klok F.A., Rappold L., et al. Quality of life and functional limitations after pulmonary embolism and its prognostic relevance. J Thromb Haemost. 2019;17:1923–1934. doi: 10.1111/jth.14589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Valerio L., Grochtdreis T., Mavromanoli A.C., Farmakis I.T., Abele C., Neusius T., et al. Burden and long-term impact of pulmonary embolism on health-related quality of life: a matched cohort study. Eur J Prev Cardiol. 2025;32:1506–1514. doi: 10.1093/eurjpc/zwaf307. [DOI] [PubMed] [Google Scholar]
- 15.Martens E.S.L., Akerboom B., Baumgartner C., et al. A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study. Thromb Res. 2026;263 doi: 10.1016/j.thromres.2026.109745. [DOI] [PubMed] [Google Scholar]
- 16.Akerboom B., Martens E.S.L., Stals M.A.M., Brouwer R.E., Coppens M., Costantino G., et al. YEARS algorithm for diagnosis of suspected pulmonary embolism in patients with cancer: a randomized clinical trial. JAMA. 2026;336:655–663. doi: 10.1001/jama.2026.10676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Tritschler T., Kraaijpoel N., Girard P., Büller H.R., Langlois N., Righini M., et al. Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: communication from the SSC of the ISTH. J Thromb Haemost. 2020;18:1495–1500. doi: 10.1111/jth.14769. [DOI] [PubMed] [Google Scholar]
- 18.Le Gal G., Carrier M., Castellucci L.A., Cuker A., Hansen J.B., Klok F.A., et al. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. J Thromb Haemost. 2021;19:297–303. doi: 10.1111/jth.15138. [DOI] [PubMed] [Google Scholar]
- 19.Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694. doi: 10.1111/j.1538-7836.2005.01204.x. [DOI] [PubMed] [Google Scholar]
- 20.Cohn D.M., Nelis E.A., Busweiler L.A., Kaptein A.A., Middeldorp S. Quality of life after pulmonary embolism: the development of the PEmb-QoL questionnaire. J Thromb Haemost. 2009;7:1044–1046. doi: 10.1111/j.1538-7836.2009.03341.x. [DOI] [PubMed] [Google Scholar]
- 21.Klok F.A., Cohn D.M., Middeldorp S., Scharloo M., Büller H.R., van Kralingen K.W., et al. Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost. 2010;8:523–532. doi: 10.1111/j.1538-7836.2009.03726.x. [DOI] [PubMed] [Google Scholar]
- 22.Rochat M., Méan M., Limacher A., Hugli O., Klok F.A., Cohn D.M., et al. Quality of life after pulmonary embolism: validation of the French version of the PEmb-QoL questionnaire. Health Qual Life Outcomes. 2014;12:174. doi: 10.1186/s12955-014-0174-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Frey P.M., Méan M., Limacher A., Leiss W., Schwab N., Rochat M., et al. Quality of life after pulmonary embolism: prospective validation of the German version of the PEmb-QoL questionnaire. Thromb Res. 2015;135:1087–1092. doi: 10.1016/j.thromres.2015.03.031. [DOI] [PubMed] [Google Scholar]
- 24.Gwozdz A.M., de Jong C.M.M., Fialho L.S., Likitabhorn T., Sossi F., Jaber P.B., et al. Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation. Lancet Haematol. 2022;9:e698–e706. doi: 10.1016/S2352-3026(22)00215-0. [DOI] [PubMed] [Google Scholar]
- 25.Valerio L., Mavromanoli A.C., Barco S., Abele C., Becker D., Bruch L., et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022;43:3387–3398. doi: 10.1093/eurheartj/ehac206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Cohen A.T., Creeper K.J., Alikhan R., Er C., Connors J.M., Huisman M.V., et al. Early time courses of recurrent venous thromboembolism and bleeding during apixaban or dalteparin therapy for patients with cancer. Thromb Haemost. 2024;124:676–683. doi: 10.1055/s-0043-1778642. [DOI] [PubMed] [Google Scholar]
- 27.NIV Antitrombotisch beleid. https://richtlijnendatabase.nl/richtlijn/antitrombotisch_beleid/startpagina_-_antitrombotisch_beleid.html
- 28.Noble S., Banerjee S., Pease N.J. Management of venous thromboembolism in far-advanced cancer: current practice. BMJ Support Palliat Care. 2022;12:e834–e837. doi: 10.1136/bmjspcare-2019-001804. [DOI] [PubMed] [Google Scholar]
- 29.Huisman B.A.A., Geijteman E.C.T., Arevalo J.J., Dees M.K., van Zuylen L., Szadek K.M., et al. Use of antithrombotics at the end of life: an in-depth chart review study. BMC Palliat Care. 2021;20:110. doi: 10.1186/s12904-021-00786-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Farmakis I.T., Barco S., Mavromanoli A.C., Konstantinides S.V., Valerio L. Performance status and long-term outcomes in cancer-associated pulmonary embolism: insights from the Hokusai-VTE cancer study. JACC CardioOncol. 2022;4:507–518. doi: 10.1016/j.jaccao.2022.07.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Akaberi A., Klok F.A., Cohn D.M., Hirsch A., Granton J., Kahn S.R. Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life. J Thromb Haemost. 2018;16:2454–2461. doi: 10.1111/jth.14302. [DOI] [PubMed] [Google Scholar]
- 32.Madsen S.F., Christensen D.M., Strange J.E., Nouhravesh N., Kümler T., Gislason G., et al. Short- and long-term mortality for patients with and without a cancer diagnosis following pulmonary embolism in Denmark, 2000 to 2020: a nationwide study. J Am Heart Assoc. 2023;12 doi: 10.1161/JAHA.123.030191. [DOI] [PMC free article] [PubMed] [Google Scholar]
